|Bid||0.6500 x 1300|
|Ask||0.9700 x 800|
|Day's Range||0.9300 - 0.9765|
|52 Week Range||0.7100 - 3.4400|
|Beta (3Y Monthly)||3.45|
|PE Ratio (TTM)||N/A|
|Earnings Date||Sep 17, 2019 - Sep 23, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||37.00|
As an investor, mistakes are inevitable. But really bad investments should be rare. So take a moment to sympathize...
Forward Pharma A/S (FWP) (“We,” “Forward” or the “Company” and, together with its subsidiaries, the “Group”), today reported consolidated financial results for the year ended December 31, 2018. During the year ended December 31, 2017, we recognized as revenue the $1.25 billion nonrecurring non-refundable fee (“Non-refundable Fee”) that was received during February 2017 in connection with the Settlement and License Agreement (“License Agreement”) entered into with two wholly owned subsidiaries of Biogen, Inc. (collectively, “Biogen”).
Forward Pharma A/S (FWP) (the “Company”) today announced that Dr. Claus Bo Svendsen, the Company’s Chief Executive Officer, will participate in the DKBIO2019 life science investor conference in New York, NY. Dr. Svendsen will present a corporate update on Thursday, April 11, 2019 at 1:00 PM ET and will be available for one-on-one meetings. Forward Pharma A/S is a Danish biopharmaceutical company that commenced development in 2005 of a proprietary formulation of DMF for the treatment of inflammatory and neurological indications.
The U.S. Court of Appeals for the Federal Circuit said it agreed with a March 2017 ruling by the Patent Trial and Appeal Board that freed Biogen (BIIB.O) from future royalty payments to Forward. Biogen did not immediately respond to a request for comment. The companies had been locked in a dispute over patents for dimethyl fumarate, the key active ingredient in Tecfidera, the leading oral MS treatment.
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that struck 52-week highs on Sept. 19.) Acceleron Pharma Inc (NASDAQ: XLRN ...